Abstract
Antibodies for therapy and diagnostics make up one of the fastest growing segments of the biopharmaceutical market. This review provides an overview of methods and processes for the selection and production of therapeutic and diagnostic recombinant proteins, including monoclonal and polyclonal antibodies. This overview also includes a comparative economic summary of current and some potential expression systems for manufacture of these highly functional recombinant proteins and antibodies, and explores the future direction of the antibody industry.
Keywords: Antibodies, antibody production, biosimilars, comparative economics, downstream processing, expression pathways, operational excellence, immunotherapeutics, monoclonal and polyclonal antibody production, process efficiency improvement, recombinant proteins, six-sigma, smart systems, therapeutic protein production, yield economics